阿替利珠单克隆抗体联合贝伐珠单克隆抗体在晚期肝细胞癌一线治疗中的临床疗效

Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced hepatocellular carcinoma

原发性肝癌已成为全世界第六大常被诊断的恶性肿瘤和第三大恶性肿瘤死亡原因,每年约50%新发肝癌在我国,其中肝细胞癌约占80%。肝细胞癌的非手术治疗不断取得突破,笔者报道1例肝细胞癌伴肝内转移、门静脉左支癌栓病人,经阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗的临床经验,其研究结果显示:肿瘤达到持续部分缓解,且无肝、肾功能损害等不良反应,病人生命质量提高。

Primary hepatic carcinoma has ranked as the sixth most commonly diagnosed cancer and the third leading cause of cancer death.China shares about 50%of new liver cancer cases,including 80%of hepatic carcinoma.Non-surgical therapy continues to make breakthroughs.The authors report a case of hepatic carcinoma with intrahepatic metastasis and tumor thrombus in the left portal vein,which has achieved continious partial response after the treatment of atezolizumab combined with bevacizumab,without adverse reactions such as liver and kidney function damage.The life quality of the patient was improved,showing safety and efficacy of the treatment.